ArticleScience advances2026
Accessory microRNA byproducts expand RNA interference via microprocessor-mediated cleavage activation.
Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA medicine is a promisingly expanding field in modern health care, but its use in genetically complex diseases, like cancer, has been challenging, mainly due to their reliance on multiple abnormal pathways. Here, we describe a microRNA-based platform that exploits previously unrecognized features of microRNA processing. Leveraging a microprocessor-dependent, cleave-activation strategy, this design allows us to expand biological impact by simultaneously up- and down-regulating desired microRNAs, while using them as structural enablers for other short, noncoding RNAs, such as aptamers. We demonstrate its biological potential in a glioblastoma model, where the simultaneous bidirectional modulation of five among the most deregulated microRNAs results in critical mass interference against the tumor. In parallel, microRNA-mediated chaperoning of an anti-p50 aptamer within the platform allows us to selectively block the nuclear factor κB pathway, a difficult-to-drug target. This work highlights the potential of chimeric microRNA clusters as an emerging therapeutic concept for cancer and other similarly multifactorial diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.